Cargando…
Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients
Myeloproliferative neoplasms (MPNs) are characterized by an increased risk of thrombosis and bleeding. Vitamin K antagonists (VKAs) are the historic anticoagulant recommended for use in MPNs. Direct oral anticoagulants (DOACs) are being increasingly used in general and cancer populations. However, D...
Autores principales: | How, Joan, Story, Charlotte, Ren, Siyang, Neuberg, Donna, Rosovsky, Rachel P., Hobbs, Gabriela S., Connors, Jean M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571422/ https://www.ncbi.nlm.nih.gov/pubmed/34741012 http://dx.doi.org/10.1038/s41408-021-00566-5 |
Ejemplares similares
-
Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients
por: How, Joan, et al.
Publicado: (2021) -
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
por: How, Joan, et al.
Publicado: (2020) -
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients
por: How, Joan, et al.
Publicado: (2022) -
Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections
por: How, Joan, et al.
Publicado: (2022) -
Risk Factors for Death or Cardiovascular Events after Acute Coronary Syndrome in Patients with Myeloproliferative Neoplasms
por: Leiva, Orly, et al.
Publicado: (2023)